STRATEGIES FOR STUDYING BRAIN DISORDERS

Vol.10 Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and Treatment

Vol.10 Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and Treatment

Editors:Tomás Palomo, Richard J. Beninger, Richard M. Kostrzewa

June 2013

Publisher: Springer Science + Business Media, LLC, 233 Spring Street, New York, NY 10013, USA

ISBN: 978-1-4614-7263-6

Pages: 433

Congresess

Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and Treatment

Mojácar (Almería)

October 14 - 18 2009

The content of this congress, together with other contributions on this topic, will be collected in vol. 10 of the series "Strategies for studying Brain Disorders". To be Published mid way through 2010.

PROGRAMME

  • Tomás Palomo, Spain
    Opening remarks
  • Patrick McGorry, Australia
    Clinical staging: a heuristic framework for intervention and understanding the pathophysiological basis of disorders

S1. BEYOND GENES IN NEUROPSYCHIATRIC DISORDERS: EPIGENETICS AND BIOMARKERS

  • Pierre Sokoloff, France
    Beyond genes in neuropsychiatric disorders
  • Barry Keverne, UK
    Epigenetically regulated imprinted genes in foetal programming
  • Renaud Massart, France
    Epigenetic function of the GPCR GPR88 in cortical neurons
  • Janet Hoenicka, Spain
    ANKK1 expression study: uncovering the biological bases of TaqIA-associated phenotypes
  • Eduardo Rodriguez-Farré, Spain
    Biomarkers of neurodevelopmental exposure to methylmercury
  • Isidro Ferrer, Spain
    Methylation of gene promoters in post-mortem brain tissue
  • Norbert Müller, Germany
    Inflamatory biomarkers and depression

S2. STAGING MOOD DISORDERS

  • Thomas N Chase, USA
    Apathy in brain disease: diagnosis, pathophysiology and treatment
  • Ian Reid, UK
    Staging antidepressant treatment
  • Eduard Vieta, Spain
    Staging bipolar disorders

S3. STAGING NEURODEGENERATIVE PROGRESSION

  • Trevor Archer, Sweden
    MPTP-induced deficits: Effects of Physical Exercise
  • Kurt A Jellinger, Austria
    Staging in Alzheimer’s disease: implications for diagnosis and treatment
  • Kiminobu Sugaya, USA
    Arresting progression of neurodegenerative disorder
  • Peter Riederer, Germany
    Diabetes Type II: a risk factor for Depression - Parkinson - Alzheimer

S4. STAGING THROUGH THE LIFE SPAN

  • Bita Moghaddam, USA
    Behavioral differences between adolescents and adults are modulated by motivational factors
  • Patricio O´Donnell, USA
    Adolescent maturation of cortical dopamine
  • Beatriz Luna, USA
    Maturation of brain systems underlying the development of cognitive control from childhood to adulthood
  • Celso Arango, Spain
    Longitudinal brain changes in chid and adolescent first-episode psychosis
  • Aysenil Belger, USA
    The neuronal circuitry of autism
  • Louk Vanderschuren, The Netherlands
    Neurobiology of social reward: insights from play behaviour in adolescent rats
  • Giovanni Laviola, Italy
    Critical age windows in neurodevelopmental psychiatric diseases: evidence from animal models

S5. STAGING PSYCHOTIC DISORDERS

  • In memoriam of Siegfried Tuinier
  • Richard Beninger, Canada
    Antipsychotic medications and memory in newly diagnosed schizophrenic patients
  • Robin Murray, UK
    Why look for animal models of schizophrenia when drug-induced psychosis provides such a good model?
  • Philip McGuire, UK
    Brain imaging in the early stages of psychosis: from at risk mental state to first episode
  • Richard M Kostrzewa, USA
    Stereotypic progressions in psychotic behaviour
  • Ralf Pukrop, Germany
    Neurocognitive indicators for a transition to psychosis
  • José Luis Vázquez-Barquero, Spain
    Clinical outcome following prescribed neuroleptic discontinuation in first episode psychosis
  • Anissa Abi-Dargham, USA
    A focus on dopamine through the stages of schizophrenia

S6. STAGING COGNITIVE DISORDERS

  • Klaus Ebmeier, UK
    Imaging markers of mild cognitive impairment and Alzheimer ´s disease
  • Jennifer L Whitwell, USA
    Progression of atrophy in Alzheimer’s disease and related disorders
  • Iván Izquierdo/ Jorge H Medina, Brazil
    Mechanisms of memory persistence
  • José Maria Delgado, Spain
    Functional basis of cognitive processes in transgenic mice
  • Paul Ince, UK
    Patterns of alpha-synucleinopathy in Alzheimer’s disease
  • Martin Cammarota, Brazil
    Ventral tegmental area regulates the persistent storage of fear-motivated memories
  • Carlos Acuña, Spain
    Decision making, behavioral supervision and learning
  • Antonio Lobo, Spain
    Staging of cognitive impairment and incidence of dementia: implications for prevention

S7. STAGED NEUROPLASTICITY IN NEUROPSYCHIATRIC DISORDERS

  • Marina Wolf, USA
    Progressive dysregulation of glutamate synapses in addiction
  • Peter Kalivas, USA
    The glutamate homeostasis hypothesis of addiction
  • Anthony A Grace, USA
    Stress, drug abuse and schizophrenia: common pathophysiological variables underlying dopamine system dysregulation
  • Charles Bradberry, USA
    Modeling the emergence of addiction related cognitive impairment with longitudinal studies in monkeys
  • Robert M Post, USA
    Mechanisms of illness progression in the recurrent affective disorders
  • Tomás Palomo, Spain
    Concluding Remarks

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+